2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2013
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder
Diniz J, Costa D, Cassab R, Pereira C, Miguel E, Shavitt R. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. Journal Of Psychopharmacology 2013, 28: 603-611. PMID: 24288238, DOI: 10.1177/0269881113512042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsBody Dysmorphic DisordersBrazilClomipramineComorbidityDrug Therapy, CombinationFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderProspective StudiesQuetiapine FumarateRisk FactorsTreatment OutcomeConceptsBody dysmorphic disorderComorbid body dysmorphic disorderPharmacological trialsDysmorphic disorderAdult obsessive-compulsive disorder (OCD) patientsSequential treatment strategyObsessive-compulsive disorder patientsSequential treatmentFluoxetine monotherapyClinical characteristicsObsessive-compulsive disorderInitial severityTreatment strategiesDisorder patientsTreatment groupsPatientsWorse responseBDD patientsEffects of sexGEE modelTrialsDisordersSequential trialsWeeksType of augmentation
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramineAssociation study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment
Miguita K, Cordeiro Q, Shavitt R, Miguel E, Vallada H. Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arquivos De Neuro-Psiquiatria 2011, 69: 283-287. PMID: 21625751, DOI: 10.1590/s0004-282x2011000300003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, TricyclicClomipramineDopamine Plasma Membrane Transport ProteinsFemaleGene FrequencyGenotypeHumansMaleMutationNorepinephrine Plasma Membrane Transport ProteinsObsessive-Compulsive DisorderPolymorphism, GeneticReceptors, SerotoninSerotonin Plasma Membrane Transport ProteinsYoung Adult
2009
Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial
Diniz J, Shavitt R, Pereira C, Hounie A, Pimentel I, Koran L, Dainesi S, Miguel E. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. Journal Of Psychopharmacology 2009, 24: 297-307. PMID: 19164490, DOI: 10.1177/0269881108099423.Peer-Reviewed Original Research
2006
Clinical features associated with treatment response in obsessive-compulsive disorder
Shavitt R, Belotto C, Curi M, Hounie A, Rosário-Campos M, Diniz J, Ferrão Y, Pato M, Miguel E. Clinical features associated with treatment response in obsessive-compulsive disorder. Comprehensive Psychiatry 2006, 47: 276-281. PMID: 16769302, DOI: 10.1016/j.comppsych.2005.09.001.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderClinical featuresPharmacological treatmentTreatment responseEarly onsetConsecutive adult patientsFourth Edition criteriaSensory phenomenaEarly-onset obsessive-compulsive disorderYale-Brown ObsessiveOral clomipramineClomipramine treatmentAdult patientsPoor prognosisPoor responseSao Paulo SchoolDisorders ClinicTic disordersEdition criteriaScore decreaseFavorable responseLinear regression analysisMental disordersStatistical ManualDisorders
2004
Treatment–response by age at onset in obsessive–compulsive disorder
Fontenelle L, do Rosário-Campos M, Mendlowicz M, Ferrão Y, Versiani M, Miguel E. Treatment–response by age at onset in obsessive–compulsive disorder. Journal Of Affective Disorders 2004, 83: 283-284. PMID: 15555726, DOI: 10.1016/j.jad.2004.07.007.Peer-Reviewed Original Research
2003
How to treat OCD in patients with Tourette syndrome
Miguel E, Shavitt RG, Ferrão YA, Brotto SA, Diniz JB. How to treat OCD in patients with Tourette syndrome. Journal Of Psychosomatic Research 2003, 55: 49-57. PMID: 12842231, DOI: 10.1016/s0022-3999(02)00583-4.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsObsessive-compulsive disorderTourette syndromeCognitive behavior therapyOCD patientsCircuit-based therapiesGonadal hormone systemsWorse treatment responsePresence of ticsRefractory patientsAutoimmune processReuptake inhibitorsSuch patientsCombined therapyResistant casesTreatment responseDrug treatmentPharmacological approachesNew therapiesPatientsEffective psychological interventionsTherapyHormone systemPsychological interventions
2001
Adults With Early-Onset Obsessive-Compulsive Disorder
Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC. Adults With Early-Onset Obsessive-Compulsive Disorder. American Journal Of Psychiatry 2001, 158: 1899-1903. PMID: 11691698, DOI: 10.1176/appi.ajp.158.11.1899.Peer-Reviewed Original ResearchConceptsSymptom onsetObsessive-compulsive disorderSelective serotonin reuptake inhibitorsOCD patientsSerotonin reuptake inhibitorsEarlier symptom onsetEarly-onset groupLater symptom onsetOnset obsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleComorbid tic disordersAdult OCD patientsObsessive Compulsive ScaleReuptake inhibitorsAdult outpatientsTic disordersTreatment outcomesOCD symptom onsetBimodal ageEarly onsetHeterogeneous disorderCompulsive ScaleDisordersAgePatients